Company: VRCA
Filing Date: 2025-12-30
Form Type: 8-K
Source: 0001193125-25-335824
Chunk: 0

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-30
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

Appointment of Charles Frantzreb as Director

On December 26, 2025, the Board of Directors (the “ Board”) of Verrica Pharmaceuticals Inc. (the “ Company”) appointed Charles Frantzreb to serve as a director of the Company effective immediately. Dr. Frantzreb will serve as a Class III director whose initial term is scheduled to expire at the 2027 annual meeting of stockholders. Dr. Frantzreb was designated for service on the Board by Caligan Partners LP (“ Caligan”) pursuant to that certain Securities Purchase Agreement, dated as of November 23, 2025 by and among the Company and certain institutional investors party thereto. Additional information about Dr. Frantzreb is set forth below.

Charles Frantzreb, age 36, has served as a Partner at Caligan, a therapeutics-dedicated investment firm, since December 2024. Prior to joining Caligan, Dr. Frantzreb served as a Senior Analyst at Great Point Partners, a healthcare-dedicated long/short hedge fund, from 2020 to November 2024, where he covered oncology investments for the firm. Prior to Great Point Partners, he worked as an equity research associate at Piper Sandler from 2018 to 2020. Dr. Frantzreb earned his M. D. from the University of Pennsylvania and his B. A. from Cornell University.

There is no family relationship between Dr. Frantzreb and any of the Company’s other directors or executive officers. The Company is not aware of any transaction involving Dr. Frantzreb requiring disclosure under Item 404(a) of Regulation S-K. Dr. Frantzreb has entered into the Company’s standard form of indemnification agreement.

Equity Compensation Matters

On December 23, 2025, the Compensation Committee of the Board approved the grant of options to the Company’s employees and management, including Jayson Rieger, the Company’s President and Chief Executive Officer, and approved the grant of restricted stock units to John Kirby, the Company’s Interim Chief Financial Officer, pursuant to the Company’s 2018 Equity Incentive Plan (the “2018 Plan”). The Compensation Committee determined such grants are appropriate to provide long-term incentives that align the interests of the Company’s employees with the interests of stockholders. In making its decision